Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$3.52 USD
-0.24 (-6.38%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $3.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.52 USD
-0.24 (-6.38%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $3.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
by Zacks Equity Research
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of 20% and 62.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -20.51% and 54.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -2,300% and 85.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 26.92% and 15.53%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More
by Zacks Equity Research
Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
by Zacks Equity Research
Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinum-sensitive ovarian cancer.
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -26.83% and 62.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 17.19% and 22.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
by Zacks Equity Research
Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.
Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?
by Zacks Equity Research
Here is how Aerie Pharmaceuticals (AERI) and Mersana Therapeutics, Inc. (MRSN) have performed compared to their sector so far this year.
Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
by Zacks Equity Research
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
by Zacks Equity Research
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Mersana Therapeutics, Inc. (MRSN)? Wall Street Analysts Think 256%
by Zacks Equity Research
The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.